Etorykoksyb w terapii bólu w gabinecie lekarza praktyka Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
kwi 9, 2025
Słowa kluczowe:
etorykoksyb, ból, choroba zwyrodnieniowa stawów, reumatoidalne zapalenie stawów
##plugins.themes.bootstrap3.article.main##
Abstrakt
Etorykoksyb – selektywny inhibitor cyklooksygenazy 2 – został wprowadzony do terapii blisko 20 lat temu. Okazał się skutecznym lekiem przeciwzapalnym i przeciwbólowym w wielu przewlekłych chorobach układu ruchu, zwłaszcza chorobie zwyrodnieniowej i reumatoidalnym zapaleniu stawów. W opracowaniu uwzględniono najistotniejsze aspekty terapii etorykoksybem z uwzględnieniem wskazań, farmakodynamiki, farmakokinetyki oraz potencjalnych nowych zastosowań. Zebrane doświadczenia poparte wynikami badań klinicznych powinny pomóc w dostosowaniu terapii bólu zapalnego do indywidualnych potrzeb pacjenta. Ostatecznym celem opracowania ma być uczynienie terapii etorykoksybem jeszcze bardziej skuteczną i bezpieczną w praktyce lekarza podstawowej opieki zdrowotnej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rupiński, R. (2025). Etorykoksyb w terapii bólu w gabinecie lekarza praktyka . Medycyna Faktów , 18(1(66), 78-83. https://doi.org/10.24292/01.MF.0125.12
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Wikipedia. Etoricoxib.
2. Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003; 19: 725-36.
3. Leung AT, Malmstrom K, Gallacher AE et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, doubl-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002; 18: 49-58.
4. Bingham OC, Sebba AI, Rubin BR et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology. 2007; 46: 496-507.
5. Wiesenhutter CW, Boice JA, Ko A et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo controlled trial. Mayo Clin Proc. 2005; 80: 470-9.
6. Bickham K, Kivitz AJ, Mehta A et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331. http://doi.org/10.1186/s12891-016-1170-0.
7. Ramiro S, Nikiphorou E, Sepriano A et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023; 82(1): 19-34.
8. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta‑analysis of randomized, double‑blinded, controlled trials. Exp Ther Med. 2020; 19: 3031-41.
9. van Durme CMPG, Wechalekar MD, Buchbinder R et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014; 9: CD010120. http://doi.org/10.1002/14651858.
10. Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014; 2014(5): CD004309. http://doi.org/10.1002/14651858.
11. Lluch E, Torres R, Nijs J et al. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain. 2014; 18(10): 1367e75.
12. Renner B, Zacher J, Buvanendran A et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Schmiedeb Arch Pharmacol. 2010; 381: 127e36.
13. Moss P, Benson HAE, Will R et al. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017; 25(11): 1781-91.
14. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016; 157(8): 1634-44.
15. Woroń J. Zastosowanie etorykoksybu w bólu zapalnym. Kiedy jest lekiem z wyboru? Lekarz POZ. 2023; 2: 99-104.
16. Nakata K, Hanai T, Take Y et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018; 26: 1263-73.
17. https://indeks.mp.pl/leki/desc.php?id=18552 (dostęp 08.04.2025.).
18. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369: 465-73.
19. Hunt RH, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003; 98: 1725-33.
20. Kwiatkowska B, Majdan M, Mastalerz-Migas A et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017; 55(6): 290-7.
21. Walker Ch. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. Int J Rheumatol. 2018; 2018: 1302835.
22. Jagannathan H, Thota A, Kumarappa AK et al. A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital. J Drug Assess. 2020; 9(1): 60-5.
23. Birbara CA, Puopolo AD, Munoz DR et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain. 2003; 4(6): 307-15.
24. Zerbini C, Ozturk ZE, Grifka J et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005; 21(12): 2037-49.
25. Karmakar A, Arora S, Singal R et al. The Efficacy and Safety of a Combination of Thiocolchicoside and Etoricoxib in Low Back Pain (ESCoTEL): A Randomized Active-Controlled Trial. Cureus. 2023; 15(10): e47621.
2. Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003; 19: 725-36.
3. Leung AT, Malmstrom K, Gallacher AE et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, doubl-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin. 2002; 18: 49-58.
4. Bingham OC, Sebba AI, Rubin BR et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology. 2007; 46: 496-507.
5. Wiesenhutter CW, Boice JA, Ko A et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo controlled trial. Mayo Clin Proc. 2005; 80: 470-9.
6. Bickham K, Kivitz AJ, Mehta A et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331. http://doi.org/10.1186/s12891-016-1170-0.
7. Ramiro S, Nikiphorou E, Sepriano A et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023; 82(1): 19-34.
8. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta‑analysis of randomized, double‑blinded, controlled trials. Exp Ther Med. 2020; 19: 3031-41.
9. van Durme CMPG, Wechalekar MD, Buchbinder R et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014; 9: CD010120. http://doi.org/10.1002/14651858.
10. Clarke R, Derry S, Moore RA. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2014; 2014(5): CD004309. http://doi.org/10.1002/14651858.
11. Lluch E, Torres R, Nijs J et al. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain. 2014; 18(10): 1367e75.
12. Renner B, Zacher J, Buvanendran A et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Schmiedeb Arch Pharmacol. 2010; 381: 127e36.
13. Moss P, Benson HAE, Will R et al. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017; 25(11): 1781-91.
14. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016; 157(8): 1634-44.
15. Woroń J. Zastosowanie etorykoksybu w bólu zapalnym. Kiedy jest lekiem z wyboru? Lekarz POZ. 2023; 2: 99-104.
16. Nakata K, Hanai T, Take Y et al. Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2018; 26: 1263-73.
17. https://indeks.mp.pl/leki/desc.php?id=18552 (dostęp 08.04.2025.).
18. Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369: 465-73.
19. Hunt RH, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003; 98: 1725-33.
20. Kwiatkowska B, Majdan M, Mastalerz-Migas A et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017; 55(6): 290-7.
21. Walker Ch. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. Int J Rheumatol. 2018; 2018: 1302835.
22. Jagannathan H, Thota A, Kumarappa AK et al. A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital. J Drug Assess. 2020; 9(1): 60-5.
23. Birbara CA, Puopolo AD, Munoz DR et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain. 2003; 4(6): 307-15.
24. Zerbini C, Ozturk ZE, Grifka J et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005; 21(12): 2037-49.
25. Karmakar A, Arora S, Singal R et al. The Efficacy and Safety of a Combination of Thiocolchicoside and Etoricoxib in Low Back Pain (ESCoTEL): A Randomized Active-Controlled Trial. Cureus. 2023; 15(10): e47621.